0000899243-18-024192.txt : 20180911
0000899243-18-024192.hdr.sgml : 20180911
20180911163627
ACCESSION NUMBER: 0000899243-18-024192
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180907
FILED AS OF DATE: 20180911
DATE AS OF CHANGE: 20180911
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: FISHMAN ROBERT S
CENTRAL INDEX KEY: 0001232237
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-50679
FILM NUMBER: 181065191
MAIL ADDRESS:
STREET 1: 2071 STIERLIN COURT
CITY: MOUNTAIN VIEW
STATE: CA
ZIP: 94043
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CORCEPT THERAPEUTICS INC
CENTRAL INDEX KEY: 0001088856
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 770487658
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 149 COMMONWEALTH DRIVE
CITY: MENLO PARK
STATE: CA
ZIP: 94025
BUSINESS PHONE: 650.688.8803
MAIL ADDRESS:
STREET 1: 149 COMMONWEALTH DRIVE
CITY: MENLO PARK
STATE: CA
ZIP: 94025
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-09-07
0
0001088856
CORCEPT THERAPEUTICS INC
CORT
0001232237
FISHMAN ROBERT S
C/O CORCEPT THERAPEUTICS INCORPORATED
149 COMMONWEALTH DRIVE
MENLO PARK
CA
94025
0
1
0
0
Chief Medical Officer
Common Stock
2018-09-07
4
M
0
8000
3.51
A
8000
D
Common Stock
2018-09-07
4
S
0
8000
14.5666
D
0
D
Stock Option (Right to Buy)
3.51
2018-09-07
4
M
0
8000
0.00
D
2025-09-29
Common Stock
8000
345000
D
These transactions were made pursuant to the terms of a 10b5-1 plan in effect at the time of sale of the shares.
Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $14.22 to $14.81 per share. Detailed information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.
Shares subject to this stock option vest and become exercisable at the rate of 25% of the total number at the first anniversary of September 28, 2015. Thereafter, 1/48th of the total number of shares subject to this option grant vests and becomes exercisable on each monthly anniversary, so that the total number of shares subject to this option becomes fully vested and exercisable on September 28, 2019.
/s/ G. Charles Robb, Attorney-in-Fact for Robert S. Fishman
2018-09-11